Detailed explanation of the working principle and therapeutic mechanism of Upadacitinib

Upadatinib is an oral selective Januskinase1 (JAK1) inhibitor, which is a small molecule targeted drug. JAK family includes JAK1, JAK2 Kinases such as , JAK3 and TYK2 are involved in the signal transduction of multiple cytokine receptors and regulate immune responses and inflammatory processes. Upadatinib highly selectively inhibits the kinase activity of JAK1 and blocks the transmission of pro-inflammatory cytokines related to the JAK-STAT signaling pathway, thereby reducing inflammatory responses and immune-mediated tissue damage.

JAK-STATThe signaling pathway plays a central role in the pathogenesis of various autoimmune and inflammatory diseases. Cytokines such asIL-6, IFN-γ, IL-2et al. activate STAT protein through JAK1 to promote the activation of inflammatory cells and the release of inflammatory mediators, leading to a chronic inflammatory state. Upadatinib blocks this pathway, reduces the production of inflammatory mediators and the excessive activation of immune cells, and effectively relieves inflammatory symptoms.

Based on its precise mechanism of action, upadatinib is widely used to treat autoimmune diseases such as rheumatoid arthritis, ankylosing spondylitis, and atopic dermatitis. Clinical trials have shown that upadatinib can not only significantly improve arthritis symptoms and functions, but also effectively relieve skin itching and lesions, and improve patients' quality of life. Compared with traditional immunosuppressants, upadatinib is administered orally and has higher selectivity and relatively lower side effects.

Although upadatinib is highly selective, long-term inhibitionJAK1 may also increase the risk of infection, especially herpes zoster and pneumonia. Patients need to regularly monitor blood routine, liver and kidney function and infection indicators during use. People with a history of severe infection or immunocompromised patients should be carefully evaluated before use. Reasonable dose adjustment and close follow-up are the keys to ensuring efficacy and safety. In general, upadatinib has become one of the important drugs for the treatment of autoimmune diseases due to its precise targeting and remarkable efficacy.

Reference materials:https://www.drugs.com/